Current understanding of Pneumocystis immunology

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Gigliotti F, Haidaris P, Haidaris C, Wright T, Van Der Meid K: Further evidence of host species-specific variation in antigens of Pneumocystis carinii using the polymerase chain reaction. J. Infect. Dis.168,191–194 (1993).
  Medline CASGoogle Scholar
• 2  Pop SM, Kolls JK, Steele C: Pneumocystis: immune recognition and evasion. Int. J. Biochem. Cell Biol.38(1),17–22 (2006).
  Medline CASGoogle Scholar
• 3  Stringer JR, Beard CB, Miller RF, Wakefield AE: A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg. Infect. Dis.8(9),891–896 (2002).
  MedlineGoogle Scholar
• 4  Redhead SA, Cushion MT, Frenkel JK, Stringer JR: Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J. Eukaryot. Microbiol.53(1),2–11 (2006).
  MedlineGoogle Scholar
• 5  Wakefield AE: Detection of DNA sequences identical to Pneumocystis carinii in samples of ambient air. J. Eukaryot. Microbiol.41(5),116S (1994).
  Medline CASGoogle Scholar
• 6  Wakefield A: DNA sequences identical to Pneumocystis cairnii f. sp. carinii and Pneumocystis carinii f. sp. hominis in samples of air spora. J. Clin. Microbiol.34,1754–1759 (1996).
  Medline CASGoogle Scholar
• 7  Cushion MT, Collins MS, Linke MJ: Biofilm formation by Pneumocystis spp. Eukaryot. Cell8(2),197–206 (2009).▪▪ Demonstrates ability to passage infectious Pneumocystis in cell-free culture medium.
  Medline CASGoogle Scholar
• 8  De Souza W, Benchimol M: Basic biology of Pneumocystis carinii: a mini review. Mem. Inst. Oswaldo Cruz100(8),903–908 (2005).
  MedlineGoogle Scholar
• 9  Wyder MA, Rasch EM, Kaneshiro ES: Quantitation of absolute Pneumocystis carinii nuclear DNA content. Trophic and cystic forms isolated from infected rat lungs are haploid organisms. J. Eukaryot. Microbiol.45(3),233–239 (1998).
  Medline CASGoogle Scholar
• 10  Cushion M, Ruffolo J, Walzer P: Analysis of the developmental stages of Pneumocystis cariniiin vitro. Lab. Invest.58,324–331 (1988).
  Medline CASGoogle Scholar
• 11  Matsumoto Y, Matsuda S, Tegoshi T: Yeast glucan in the cyst wall of Pneumocystis carinii.J. Protozool.36(1),21S–22S (1989).
  Medline CASGoogle Scholar
• 12  Smulian AG, Sesterhenn T, Tanaka R, Cushion MT: The ste3 pheromone receptor gene of Pneumocystis carinii is surrounded by a cluster of signal transduction genes. Genetics157(3),991–1002 (2001).
  Medline CASGoogle Scholar
• 13  Vohra PK, Puri V, Kottom Tj, Limper AH, Thomas CF: Pneumocystis carinii ste11, an Hmg-box protein, is phosphorylated by the mitogen activated protein kinase Pcm. Gene312,173–179 (2003).
  Medline CASGoogle Scholar
• 14  Shepp DH, Hackman RC, Conley FK, Anderson JB, Meyers JD: Toxoplasma gondii reactivation identified by detection of parasitemia in tissue culture. Ann. Intern. Med.103(2),218–221 (1985).
  Medline CASGoogle Scholar
• 15  Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG: Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J. Infect. Dis.172(2),595–598 (1995).
  Medline CASGoogle Scholar
• 16  Helweg-Larsen J: Pneumocystis jiroveci. Applied molecular microbiology, epidemiology and diagnosis. Dan. Med. Bull.51(3),251–273 (2004).
  Medline CASGoogle Scholar
• 17  Vargas Sl, Hughes WT, Santolaya ME et al.: Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin. Infect. Dis.32(6),855–861 (2001).
  Medline CASGoogle Scholar
• 18  Morgan DJ, Vargas Sl, Reyes-Mugica M, Walterspiel JN, Carver W, Gigliotti F: Identification of Pneumocystis carinii in the lungs of infants dying of sudden infant death syndrome. Pediatr. Infect. Dis. J.20(3),306–309 (2001).
  Medline CASGoogle Scholar
• 19  Lundgren B, Elvin K, Rothman LP, Ljungstrom I, Lidman C, Lundgren JD: Transmission of Pneumocystis carinii from patients to hospital staff. Thorax52(5),422–424 (1997).
  Medline CASGoogle Scholar
• 20  Miller RF, Ambrose HE, Wakefield AE: Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J. Clin. Microbiol.39(11),3877–3882 (2001).
  Medline CASGoogle Scholar
• 21  Vargas SL, Ponce CA, Gigliotti F et al.: Transmission of Pneumocystis carinii DNA from a patient with P. carinii pneumonia to immunocompetent contact health care workers. J. Clin. Microbiol.38(4),1536–1538 (2000).
  Medline CASGoogle Scholar
• 22  Hughes W: Natural mode of acquisition for de novo infection with Pneumocystis carinii. J. Infect. Dis.145,842–848 (1982).
  Medline CASGoogle Scholar
• 23  Nevez G, Raccurt C, Vincent P, Jounieaux V, Dei-Cas E: Pulmonary colonization with Pneumocystis carinii in human immunodeficiency virus-negative patients: assessing risk with blood CD4⁺ T cell counts. Clin. Infect. Dis.29(5),1331–1332 (1999).
  Medline CASGoogle Scholar
• 24  Leigh TR, Kangro HO, Gazzard BG, Jeffries DJ, Collins Jv: DNA amplification by the polymerase chain reaction to detect sub-clinical Pneumocystis carinii colonization in HIV-positive and HIV-negative male homosexuals with and without respiratory symptoms. Respir. Med.87(7),525–529 (1993).
  Medline CASGoogle Scholar
• 25  Huang L, Crothers K, Morris A et al.: Pneumocystis colonization in HIV-infected patients. J. Eukaryot. Microbiol.50(Suppl.),616–617 (2003).
  MedlineGoogle Scholar
• 26  Morris A, Wei K, Afshar K, Huang L: Epidemiology and clinical significance of Pneumocystis colonization. J. Infect. Dis.197(1),10–17 (2008).
  Medline CASGoogle Scholar
• 27  Davis JL, Welsh DA, Beard CB et al.: Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax63(4),329–334 (2008).
  Medline CASGoogle Scholar
• 28  Nevez G, Delbecq S, Raccurt C: Pneumocystis carinii trophozoites in the lungs of patients without pneumocystosis. J. Eukaryot. Microbiol.46(5),109S-110S (1999).
  Medline CASGoogle Scholar
• 29  Calderon EJ, Regordan C, Medrano FJ, Ollero M, Varela JM: Pneumocystis carinii infection in patients with chronic bronchial disease. Lancet347(9006),977 (1996).
  Medline CASGoogle Scholar
• 30  Morris A, Sciurba FC, Lebedeva IP et al.: Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am. J. Respir. Crit. Care Med.170(4),408–413 (2004).
  MedlineGoogle Scholar
• 31  Norris KA, Morris A, Patil S, Fernandes E: Pneumocystis colonization, airway inflammation, and pulmonary function decline in acquired immunodeficiency syndrome. Immunol. Res.36(1–3),175–187 (2006).▪ Discusses association and colonization of Pneumocystis.
  Medline CASGoogle Scholar
• 32  Kling HM, Shipley TW, Patil S, Morris A, Norris KA: Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques. J. Infect. Dis.199(1),89–96 (2009).
  MedlineGoogle Scholar
• 33  Krajicek BJ, Limper AH, Thomas CF Jr: Advances in the biology, pathogenesis and identification of Pneumocystis pneumonia. Curr. Opin. Pulm. Med.14(3),228–234 (2008).
  MedlineGoogle Scholar
• 34  Grimwade K, Swingler G: Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst. Rev.2,CD003508 (2003).
  Google Scholar
• 35  Kaplan JE, Hanson D, Dworkin MS et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the united states in the era of highly active antiretroviral therapy. Clin. Infect. Dis.30(Suppl. 1),S5–S14 (2000).
  MedlineGoogle Scholar
• 36  Morris A, Lundgren JD, Masur H et al.: Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis.10(10),1713–1720 (2004).
  MedlineGoogle Scholar
• 37  Cushion MT: Pneumocystis: unraveling the cloak of obscurity. Trends Microbiol.12(5),243–249 (2004).
  Medline CASGoogle Scholar
• 38  Morris A, Wachter RM, Luce J, Turner J, Huang L: Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS17(1),73–80 (2003).
  MedlineGoogle Scholar
• 39  Jain MK, Skiest DJ, Cloud JW, Jain Cl, Burns D, Berggren RE: Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999–2000. Clin. Infect. Dis.36(8),1030–1038 (2003).
  MedlineGoogle Scholar
• 40  Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF: Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985–2006. Clin. Infect. Dis.46(4),625–633 (2008).
  MedlineGoogle Scholar
• 41  Morris A: Is there anything new in Pneumocystis jirovecii pneumonia? Changes in P. jirovecii pneumonia over the course of the AIDS epidemic. Clin. Infect. Dis.46(4),634–636 (2008).
  MedlineGoogle Scholar
• 42  Sowden E, Carmichael AJ: Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia: a strategy for prevention. BMC Infect. Dis.4,42 (2004).
  MedlineGoogle Scholar
• 43  De Castro N, Pavie J, Lagrange-Xelot M, Molina JM: Pneumocystis jiroveci pneumonia in patients with cancer: is it unavoidable? Rev. Mal. Respir.24(6),741–750 (2007).
  Medline CASGoogle Scholar
• 44  Mansharamani NG, Garland R, Delaney D, Koziel H: Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest118(3),704–711 (2000).▪ Explains changing trends in epidemiology of Pneumocystis pneumonia (PCP).
  Medline CASGoogle Scholar
• 45  Thomas CF Jr, Limper AH: Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat. Rev. Microbiol.5(4),298–308 (2007).
  Medline CASGoogle Scholar
• 46  Patel R, Paya CV: Infections in solid-organ transplant recipients. Clin. Microbiol. Rev.10(1),86–124 (1997).
  Medline CASGoogle Scholar
• 47  Rodriguez M, Fishman JA: Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin. Microbiol. Rev.17(4),770–782 (2004).
  MedlineGoogle Scholar
• 48  Mikaelsson L, Jacobsson G, Andersson R: Pneumocystis pneumonia – a retrospective study 1991–2001 in Gothenburg, Sweden. J. Infect.53(4),260–265 (2006).▪▪ Retrospective study of PCP cases demonstrating those at risk are not being identified.
  MedlineGoogle Scholar
• 49  Sepkowitz KA: Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis.34(8),1098–1107 (2002).
  MedlineGoogle Scholar
• 50  Singer NG, Mccune WJ: Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Curr. Opin. Rheumatol.11(3),173–178 (1999).
  Medline CASGoogle Scholar
• 51  Li L, Sad S, Kagi D, Mosmann Tr: CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J. Immunol.158(9),4152–4161 (1997).
  Medline CASGoogle Scholar
• 52  Ellerin T, Rubin RH, Weinblatt ME: Infections and anti-tumor necrosis factor a therapy. Arthritis Rheum.48(11),3013–3022 (2003).
  Medline CASGoogle Scholar
• 53  Yukiko K, Masayoshi H, Ryuji K et al.: Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case–control study of 21 patients. Arthritis Care Res.61(3),305–312 (2009).
  Google Scholar
• 54  Stratakos G, Kalomenidis I, Papas V et al.: Cough and fever in a female with Crohn’s disease receiving infliximab. Eur. Respir. J.26(2),354–357 (2005).
  Medline CASGoogle Scholar
• 55  Nahimana A, Rabodonirina M, Bille J, Francioli P, Hauser Pm: Mutations of Pneumocystis jirovecii dihydrofolate reductase associated with failure of prophylaxis. Antimicrob. Agents Chemother.48(11),4301–4305 (2004).
  Medline CASGoogle Scholar
• 56  Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL: Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J. Biol. Chem.279(4),2817–2824 (2004).
  Medline CASGoogle Scholar
• 57  Huang L, Crothers K, Atzori C et al.: Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance. Emerg. Infect. Dis.10(10),1721–1728 (2004).
  Medline CASGoogle Scholar
• 58  Beard CB, Fox MR, Lawrence GG et al.: Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J. Infect. Dis.192(10),1815–1818 (2005).
  Medline CASGoogle Scholar
• 59  Crothers K, Beard CB, Turner J et al.: Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS19(8),801–805 (2005).
  MedlineGoogle Scholar
• 60  Fleury J, Escudier E, Pocholle MJ, Carre C, Bernaudin JF: Cell population obtained by bronchoalveolar lavage in Pneumocystis carinii pneumonitis. Acta Cytol.29(5),721–726 (1985).
  Medline CASGoogle Scholar
• 61  Young JA, Stone JW, Mcgonigle RJ, Adu D, Michael J: Diagnosing Pneumocystis carinii pneumonia by cytological examination of bronchoalveolar lavage fluid: report of 15 cases. J. Clin. Pathol.39(9),945–949 (1986).
  Medline CASGoogle Scholar
• 62  Young KR Jr, Rankin JA, Naegel GP, Paul ES, Reynolds HY: Bronchoalveolar lavage cells and proteins in patients with the acquired immunodeficiency syndrome. An immunologic analysis. Ann. Intern. Med.103(4),522–533 (1985).
  MedlineGoogle Scholar
• 63  Gigliotti F, Ballou LR, Hughes WW, Mosley BD: Purification and initial characterization of a ferret Pneumocystis carinii surface antigen. J. Infect. Dis.158(4),848–854 (1988).
  Medline CASGoogle Scholar
• 64  Stringer JR, Keely SP: Genetics of surface antigen expression in Pneumocystis carinii.Infect. Immun.69(2),627–639 (2001).
  Medline CASGoogle Scholar
• 65  Ezekowitz RA, Williams DJ, Koziel H et al.: Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature351(6322),155–158 (1991).
  Medline CASGoogle Scholar
• 66  Koziel H, Eichbaum Q, Kruskal BA et al.: Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J. Clin. Invest.102(7),1332–1344 (1998).▪▪ Shows that the alveolar macrophage mannose receptor is downregulated in HIV+ individuals.
  Medline CASGoogle Scholar
• 67  Fraser IP, Takahashi K, Koziel H, Fardin B, Harmsen A, Ezekowitz RA: Pneumocystis carinii enhances soluble mannose receptor production by macrophages. Microbes Infect.2(11),1305–1310 (2000).
  Medline CASGoogle Scholar
• 68  Zhang J, Zhu J, Bu X et al.: Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages. Mol. Biol. Cell16(2),824–834 (2005).
  Medline CASGoogle Scholar
• 69  Zhang J, Zhu J, Imrich A, Cushion M, Kinane TB, Koziel H: Pneumocystis activates human alveolar macrophage NF-κB signaling through mannose receptors. Infect. Immun.72(6),3147–3160 (2004).
  Medline CASGoogle Scholar
• 70  Zhang J, Tachado SD, Patel N et al.: Negative regulatory role of mannose receptors on human alveolar macrophage proinflammatory cytokine release in vitro. J. Leukoc. Biol.78(3),665–674 (2005).
  Medline CASGoogle Scholar
• 71  Swain SD, Lee SJ, Nussenzweig MC, Harmsen AG: Absence of the macrophage mannose receptor in mice does not increase susceptibility to Pneumocystis carinii infection in vivo. Infect. Immun.71(11),6213–6221 (2003).
  Medline CASGoogle Scholar
• 72  De Stefano JA, Cushion MT, Puvanesarajah V, Walzer PD: Analysis of Pneumocystis carinii cyst wall. II. Sugar composition. J. Protozool.37(5),436–441 (1990).
  Medline CASGoogle Scholar
• 73  De Stefano JA, Myers JD, Du Pont D, Foy JM, Theus SA, Walzer PD: Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J. Eukaryot. Microbiol.45(3),334–343 (1998).
  Medline CASGoogle Scholar
• 74  Vassallo R, Standing J, Limper AH: β-glucan from Pneumocystis carinii stimulates TNF-α release from alveolar macrophages. J. Eukaryot. Microbiol.46(5),145S (1999).
  Medline CASGoogle Scholar
• 75  Lebron F, Vassallo R, Puri V, Limper AH: Pneumocystis carinii cell wall β-glucans initiate macrophage inflammatory responses through NF-κB activation. J. Biol. Chem.278(27),25001–25008 (2003).
  Medline CASGoogle Scholar
• 76  Vassallo R, Kottom TJ, Standing JE, Limper AH: Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am. J. Respir. Cell Mol. Biol.25(2),203–211 (2001).
  Medline CASGoogle Scholar
• 77  Ross GD, Cain JA, Lachmann PJ: Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J. Immunol.134(5),3307–3315 (1985).
  Medline CASGoogle Scholar
• 78  Brown GD, Gordon S: Immune recognition. A new receptor for β-glucans. Nature413(6851),36–37 (2001).
  Medline CASGoogle Scholar
• 79  Steele C, Marrero L, Swain S et al.: Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 β-glucan receptor. J. Exp. Med.198(11),1677–1688 (2003).
  Medline CASGoogle Scholar
• 80  Saijo S, Fujikado N, Furuta T et al.: Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat. Immunol.8(1),39–46 (2007).
  Medline CASGoogle Scholar
• 81  Taylor MB, Phillips M, Easmon CS: Opsonophagocytosis of Pneumocystis carinii. J. Med. Microbiol.36(4),223–228 (1992).
  Medline CASGoogle Scholar
• 82  Rapaka RR, Goetzman ES, Zheng M et al.: Enhanced defense against Pneumocystis carinii mediated by a novel dectin-1 receptor fc fusion protein. J. Immunol.178(6),3702–3712 (2007).
  Medline CASGoogle Scholar
• 83  Ding K, Shibui A, Wang Y, Takamoto M, Matsuguchi T, Sugane K: Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia. Microbes Infect.7(2),195–203 (2005).
  Medline CASGoogle Scholar
• 84  Tachado SD, Zhang J, Zhu J, Patel N, Cushion M, Koziel H: Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2. J. Leukoc. Biol.81(1),205–211 (2007).
  Medline CASGoogle Scholar
• 85  Zhang C, Wang SH, Lasbury ME et al.: Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murina. Infect. Immun.74(3),1857–1864 (2006).
  Medline CASGoogle Scholar
• 86  Zhang C, Wang SH, Liao CP et al.: Toll-like receptor 2 knockout reduces lung inflammation during Pneumocystis pneumonia but has no effect on phagocytosis of Pneumocystis organisms by alveolar macrophages. J. Eukaryot. Microbiol.53(Suppl. 1),S132–S133 (2006).
  MedlineGoogle Scholar
• 87  Wang SH, Zhang C, Lasbury ME et al.: Decreased inflammatory response in Toll-like receptor 2 knockout mice is associated with exacerbated Pneumocystis pneumonia. Microbes Infect.10(4),334–341 (2008).
  Medline CASGoogle Scholar
• 88  Hollifield M, Bou Ghanem E, De Villiers WJ, Garvy BA: Scavenger receptor a dampens induction of inflammation in response to the fungal pathogen Pneumocystis carinii. Infect. Immun.75(8),3999–4005 (2007).
  Medline CASGoogle Scholar
• 89  Rooney SA, Young SL, Mendelson CR: Molecular and cellular processing of lung surfactant. FASEB J.8(12),957–967 (1994).
  Medline CASGoogle Scholar
• 90  Griese M: Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J.13(6),1455–1476 (1999).
  Medline CASGoogle Scholar
• 91  Atochina EN, Beers MF, Scanlon ST, Preston AM, Beck JM: P. Carinii induces selective alterations in component expression and biophysical activity of lung surfactant. Am. J. Physiol. Lung Cell Mol. Physiol.278(3),L599–L609 (2000).
  Medline CASGoogle Scholar
• 92  Beers MF, Atochina EN, Preston AM, Beck JM: Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J. Lab. Clin. Med.133(5),423–433 (1999).
  Medline CASGoogle Scholar
• 93  Mccormack FX, Gibbons R, Ward SR, Kuzmenko A, Wu H, Deepe Gs Jr: Macrophage-independent fungicidal action of the pulmonary collectins. J. Biol. Chem.278(38),36250–36256 (2003).
  Medline CASGoogle Scholar
• 94  O’riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC, Limper AH: Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J. Clin. Invest.95(6),2699–2710 (1995).
  MedlineGoogle Scholar
• 95  Mccormack FX, Festa AL, Andrews RP, Linke M, Walzer PD: The carbohydrate recognition domain of surfactant protein a mediates binding to the major surface glycoprotein of Pneumocystis carinii. Biochemistry36(26),8092–8099 (1997).
  Medline CASGoogle Scholar
• 96  Atochina EN, Beck JM, Scanlon ST, Preston AM, Beers MF: Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J. Lab. Clin. Med.137(6),429–439 (2001).
  Medline CASGoogle Scholar
• 97  Williams MD, Wright JR, March KL, Martin WJ II: Human surfactant protein a enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am. J. Respir. Cell Mol. Biol.14(3),232–238 (1996).
  Medline CASGoogle Scholar
• 98  Koziel H, Phelps DS, Fishman JA, Armstrong MY, Richards FF, Rose RM: Surfactant protein-A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro. Am. J. Respir. Cell Mol. Biol.18(6),834–843 (1998).
  Medline CASGoogle Scholar
• 99  Atochina EN, Beck JM, Preston AM et al.: Enhanced lung injury and delayed clearance of Pneumocystis carinii in surfactant protein A-deficient mice: attenuation of cytokine responses and reactive oxygen–nitrogen species. Infect. Immun.72(10),6002–6011 (2004).
  Medline CASGoogle Scholar
• 100  Linke MJ, Ashbaugh AD, Demland JA, Walzer PD: Pneumocystis murina colonization in immunocompetent surfactant protein a deficient mice following environmental exposure. Respir. Res.10,10 (2009).
  MedlineGoogle Scholar
• 101  Vuk-Pavlovic Z, Mo EK, Icenhour CR, Standing JE, Fisher JH, Limper AH: Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice. Am. J. Physiol. Lung Cell Mol. Physiol.290(3),L442–L449 (2006).
  Medline CASGoogle Scholar
• 102  Koziel H, Li X, Armstrong MY, Richards FF, Rose RM: Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis cariniiin vitro. Am. J. Respir. Cell Mol. Biol.23(4),452–459 (2000).
  Medline CASGoogle Scholar
• 103  Shellito JE, Kolls JK, Olariu R, Beck JM: Nitric oxide and host defense against Pneumocystis carinii infection in a mouse model. J. Infect. Dis.173(2),432–439 (1996).
  Medline CASGoogle Scholar
• 104  Downing JF, Kachel DL, Pasula R, Martin WJ 2nd: γ interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect. Immun.67(3),1347–1352 (1999).
  Medline CASGoogle Scholar
• 105  Limper AH, Hoyte JS, Standing JE: The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J. Clin. Invest.99(9),2110–2117 (1997).▪▪ Demonstrates the importance of alveolar macrophages during PCP infection through chemical depletion.
  Medline CASGoogle Scholar
• 106  Lasbury ME, Durant PJ, Bartlett MS, Smith JW, Lee CH: Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Clin. Diagn. Lab. Immunol.10(2),293–302 (2003).▪▪ Shows a correlation between macrophage counts and organism burden, and alveolar macrophage rebounding with cessation of steroid treatment versus Pneumocystis prophylaxis.
  MedlineGoogle Scholar
• 107  Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, Lee CH: Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J. Immunol.176(11),6443–6453 (2006).
  Medline CASGoogle Scholar
• 108  Lasbury ME, Merali S, Durant PJ, Tschang D, Ray CA, Lee CH: Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J. Biol. Chem.282(15),11009–11020 (2007).
  Medline CASGoogle Scholar
• 109  Liao CP, Lasbury ME, Wang SH et al.: Pneumocystis mediates overexpression of antizyme inhibitor resulting in increased polyamine levels and apoptosis in alveolar macrophages. J. Biol. Chem.284(12),8174–8184 (2009).▪ Demonstrates that Pneumocystis infection results in apoptosis of alveolar macrophages through increased polyamine levels.
  Medline CASGoogle Scholar
• 110  Brunet A, Bonni A, Zigmond MJ et al.: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell96(6),857–868 (1999).
  Medline CASGoogle Scholar
• 111  Kodama T, Hazeki K, Hazeki O, Okada T, Ui M: Enhancement of chemotactic peptide-induced activation of phosphoinositide 3-kinase by granulocyte-macrophage colony-stimulating factor and its relation to the cytokine-mediated priming of neutrophil superoxide-anion production. Biochem. J.337(Pt 2),201–209 (1999).
  Medline CASGoogle Scholar
• 112  Kamata N, Kutsuna H, Hato F et al.: Activation of human neutrophils by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor a: role of phosphatidylinositol 3-kinase. Int. J. Hematol.80(5),421–427 (2004).
  Medline CASGoogle Scholar
• 113  Lasbury ME, Durant PJ, Liao CP, Lee CH: Effects of decreased calmodulin protein on the survival mechanisms of alveolar macrophages during Pneumocystis pneumonia. Infect. Immun. (2009) (Epub ahead of print).
  MedlineGoogle Scholar
• 114  Holt PG, Haining S, Nelson DJ, Sedgwick JD: Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways. J. Immunol.153(1),256–261 (1994).
  Medline CASGoogle Scholar
• 115  Romani L: Immunity to fungal infections. Nat. Rev. Immunol.4(1),1–23 (2004).
  MedlineGoogle Scholar
• 116  Wilson CB, Lewis DB: Basis and implications of selectively diminished cytokine production in neonatal susceptibility to infection. Rev. Infect. Dis.12(Suppl. 4),S410–S420 (1990).
  MedlineGoogle Scholar
• 117  Larsen HH, Von Linstow ML, Lundgren B, Hogh B, Westh H, Lundgren JD: Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg. Infect. Dis.13(1),66–72 (2007).
  MedlineGoogle Scholar
• 118  Garvy BA, Qureshi MH: Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J. Immunol.165(11),6480–6486 (2000).
  Medline CASGoogle Scholar
• 119  Qureshi MH, Empey KM, Garvy BA: Modulation of proinflammatory responses to Pneumocystis carinii f. sp. muris in neonatal mice by granulocyte-macrophage colony-stimulating factor and IL-4: role of APCS. J. Immunol.174(1),441–448 (2005).
  Medline CASGoogle Scholar
• 120  Zheng M, Shellito JE, Marrero L et al.: CD4⁺ T cell-independent vaccination against Pneumocystis carinii in mice. J. Clin. Invest.108(10),1469–1474 (2001).
  Medline CASGoogle Scholar
• 121  Kobayashi H, Worgall S, O’connor TP, Crystal RG: Interaction of Pneumocystis carinii with dendritic cells and resulting host responses to P. carinii. J. Immunother.30(1),54–63 (2007).
  Medline CASGoogle Scholar
• 122  Carmona EM, Vassallo R, Vuk-Pavlovic Z, Standing JE, Kottom TJ, Limper AH: Pneumocystis cell wall β-glucans induce dendritic cell costimulatory molecule expression and inflammatory activation through a fas–fas ligand mechanism. J. Immunol.177(1),459–467 (2006).
  Medline CASGoogle Scholar
• 123  Rosenzweig SD, Holland SM: Phagocyte immunodeficiencies and their infections. J. Allergy Clin. Immunol.113(4),620–626 (2004).
  Medline CASGoogle Scholar
• 124  Jensen BN, Lisse IM, Gerstoft J, Borgeskov S, Skinhoj P: Cellular profiles in bronchoalveolar lavage fluid of HIV-infected patients with pulmonary symptoms: relation to diagnosis and prognosis. AIDS5(5),527–533 (1991).
  Medline CASGoogle Scholar
• 125  Sadaghdar H, Huang ZB, Eden E: Correlation of bronchoalveolar lavage findings to severity of Pneumocystis carinii pneumonia in AIDS. Evidence for the development of high-permeability pulmonary edema. Chest102(1),63–69 (1992).
  Medline CASGoogle Scholar
• 126  Swain SD, Wright TW, Degel PM, Gigliotti F, Harmsen AG: Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice. Infect. Immun.72(10),5722–5732 (2004).
  Medline CASGoogle Scholar
• 127  Pottratz ST, Reese S, Sheldon JL: Pneumocystis carinii induces interleukin 6 production by an alveolar epithelial cell line. Eur J. Clin. Invest.28(5),424–429 (1998).
  Medline CASGoogle Scholar
• 128  Benfield TL, Lundgren B, Shelhamer JH, Lundgren JD: Pneumocystis carinii major surface glycoprotein induces interleukin-8 and monocyte chemoattractant protein-1 release from a human alveolar epithelial cell line. Eur. J. Clin. Invest.29(8),717–722 (1999).
  Medline CASGoogle Scholar
• 129  Wang J, Gigliotti F, Bhagwat SP, Maggirwar SB, Wright TW: Pneumocystis stimulates mcp-1 production by alveolar epithelial cells through a JNK-dependent mechanism. Am. J. Physiol. Lung Cell Mol. Physiol.292(6),L1495–L1505 (2007).
  Medline CASGoogle Scholar
• 130  Hahn PY, Evans SE, Kottom TJ, Standing JE, Pagano RE, Limper AH: Pneumocystis carinii cell wall β-glucan induces release of macrophage inflammatory protein-2 from alveolar epithelial cells via a lactosylceramide-mediated mechanism. J. Biol. Chem.278(3),2043–2050 (2003).
  Medline CASGoogle Scholar
• 131  Wang J, Gigliotti F, Maggirwar S, Johnston C, Finkelstein JN, Wright TW: Pneumocystis carinii activates the NF-κB signaling pathway in alveolar epithelial cells. Infect. Immun.73(5),2766–2777 (2005).
  Medline CASGoogle Scholar
• 132  Evans SE, Hahn PY, Mccann F, Kottom TJ, Pavlovic ZV, Limper AH: Pneumocystis cell wall β-glucans stimulate alveolar epithelial cell chemokine generation through nuclear factor-κb-dependent mechanisms. Am. J. Respir. Cell Mol. Biol.32(6),490–497 (2005).
  Medline CASGoogle Scholar
• 133  Beck JM, Preston AM, Wilcoxen SE, Morris SB, Sturrock A, Paine R 3rd: Critical roles of inflammation and apoptosis in improved survival in a model of hyperoxia-induced acute lung injury in Pneumocystis murina-infected mice. Infect. Immun.77(3),1053–1060 (2009).▪ Demonstrates that lung epithelial cells have increased apoptosis mediated through Fas–Fas ligand interactions during PCP, particularly with the stress of hyperoxia.
  Medline CASGoogle Scholar
• 134  Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A: The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter aids cohort study group. N. Engl. J. Med.322(3),161–165 (1990).
  Medline CASGoogle Scholar
• 135  Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, Ermak TH: A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J. Clin. Invest.85(5),1686–1693 (1990).
  Medline CASGoogle Scholar
• 136  Rose CM, Kimzey SL, Green JM: The host response of CD28-deficient mice to Pneumocystis infection. Microb. Pathog.40(1),23–28 (2006).
  Medline CASGoogle Scholar
• 137  Beck JM, Blackmon MB, Rose CM, Kimzey SL, Preston AM, Green JM: T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J. Immunol.171(4),1969–1977 (2003).
  Medline CASGoogle Scholar
• 138  Wright TW, Gigliotti F, Finkelstein JN, Mcbride JT, An CL, Harmsen AG: Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J. Clin. Invest.104(9),1307–1317 (1999).
  Medline CASGoogle Scholar
• 139  Roths JB, Sidman CL: Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4⁺ but not CD8⁺ T cells into severe combined immunodeficiency mice. J. Clin. Invest.90(2),673–678 (1992).
  Medline CASGoogle Scholar
• 140  Wu AK, Cheng VC, Tang BS et al.: The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. BMC Infect. Dis.4(1),57 (2004).
  MedlineGoogle Scholar
• 141  Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM: Immunorestitution disease involving the innate and adaptive response. Clin. Infect. Dis.30(6),882–892 (2000).
  Medline CASGoogle Scholar
• 142  Koval CE, Gigliotti F, Nevins D, Demeter LM: Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin. Infect. Dis.35(4),491–493 (2002).
  MedlineGoogle Scholar
• 143  Atochina-Vasserman EN, Gow AJ, Abramova H et al.: Immune reconstitution during Pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation. J. Immunol.182(4),2277–2287 (2009).
  Medline CASGoogle Scholar
• 144  Bhagwat SP, Gigliotti F, Xu H, Wright TW: Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am. J. Physiol. Lung Cell Mol. Physiol.291(6),L1256–L1266 (2006).
  Medline CASGoogle Scholar
• 145  Swain SD, Meissner NN, Harmsen AG: CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in Pneumocystis pneumonia in B-cell-deficient mice. Am. J. Pathol.168(2),466–475 (2006).▪ Demonstrates the roles of CD4+ and CD8+ T cells during immune reconstitution disease.
  Medline CASGoogle Scholar
• 146  Hori S, Carvalho TL, Demengeot J: CD25⁺ CD4⁺ regulatory T cells suppress CD4⁺ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur. J. Immunol.32(5),1282–1291 (2002).
  Medline CASGoogle Scholar
• 147  Mckinley L, Logar AJ, Mcallister F, Zheng M, Steele C, Kolls JK: Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of Pneumocystis pneumonia. J. Immunol.177(9),6215–6226 (2006).
  Medline CASGoogle Scholar
• 148  Gigliotti F, Crow EL, Bhagwat SP, Wright TW: Sensitized CD8⁺ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia. Infect. Immun.74(11),6310–6316 (2006).
  Medline CASGoogle Scholar
• 149  Meissner NN, Lund FE, Han S, Harmsen A: CD8 T cell-mediated lung damage in response to the extracellular pathogen Pneumocystis is dependent on MHC class I expression by radiation-resistant lung cells. J. Immunol.175(12),8271–8279 (2005).
  Medline CASGoogle Scholar
• 150  Wright TW, Pryhuber GS, Chess PR, Wang Z, Notter RH, Gigliotti F: TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J. Immunol.172(4),2511–2521 (2004).
  Medline CASGoogle Scholar
• 151  Pryhuber GS, Huyck HL, Bhagwat S et al.: Parenchymal cell TNF receptors contribute to inflammatory cell recruitment and respiratory failure in Pneumocystis carinii-induced pneumonia. J. Immunol.181(2),1409–1419 (2008).
  Medline CASGoogle Scholar
• 152  Kolls JK, Habetz S, Shean MK et al.: IFN-γ and CD8⁺ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4⁺ T cells. J. Immunol.162(5),2890–2894 (1999).▪▪ Shows gene transfer of IFN-γ results in organism clearance mediated by CD8+ T cells in the absence of CD4+ T cells.
  Medline CASGoogle Scholar
• 153  Mcallister F, Steele C, Zheng M et al.: T cytotoxic-1 CD8⁺ T cells are effector cells against Pneumocystis in mice. J. Immunol.172(2),1132–1138 (2004).▪▪ Demonstrates the effector activity of T cytotoxic 1 CD8+ T cells verses the pathogenesis of T cytotoxic 2 CD8+ T cells.
  Medline CASGoogle Scholar
• 154  Mcallister F, Steele C, Zheng M, Shellito JE, Kolls JK: In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8⁺ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect. Immun.73(11),7450–7457 (2005).
  Medline CASGoogle Scholar
• 155  Mcallister F, Ruan S, Steele C et al.: Cxcr3 and IFN protein-10 in Pneumocystis pneumonia. J. Immunol.177(3),1846–1854 (2006).
  Medline CASGoogle Scholar
• 156  Chang H, Yeh HC, Su YC, Lee MH: Pneumocystis jiroveci pneumonia in patients with non-Hodgkin’s lymphoma receiving chemotherapy containing rituximab. J. Chin. Med. Assoc.71(11),579–582 (2008).
  MedlineGoogle Scholar
• 157  Daly KR, Koch J, Levin L, Walzer PD: Enzyme-linked immunosorbent assay and serologic responses to Pneumocystis jiroveci. Emerg. Infect. Dis.10(5),848–854 (2004).
  Medline CASGoogle Scholar
• 158  Bishop LR, Kovacs JA: Quantitation of anti-Pneumocystis jiroveci antibodies in healthy persons and immunocompromised patients. J. Infect. Dis.187(12),1844–1848 (2003).
  MedlineGoogle Scholar
• 159  Daly K, Koch J, Respaldiza N et al.: Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens. Clin. Microbiol. Infect.15(10),937–942 (2009).▪ Shows that geographical location plays a role in antibody responses to Pneumocystis antigens.
  Medline CASGoogle Scholar
• 160  Walzer PD, Djawe K, Levin L et al.: Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. J. Infect. Dis.199(9),1335–1344 (2009).
  MedlineGoogle Scholar
• 161  Furuta T, Fujiwara K, Yamanouchi K, Ueda K: Detection of antibodies to Pneumocystis carinii by enzyme-linked immunosorbent assay in experimentally infected mice. J. Parasitol.71(4),522–523 (1985).
  Medline CASGoogle Scholar
• 162  Walzer PD, Rutledge ME: Humoral immunity in experimental Pneumocystis carinii infection. I. Serum and bronchial lavage fluid antibody responses in rats. J. Lab. Clin. Med.97(6),820–833 (1981).
  Medline CASGoogle Scholar
• 163  Gigliotti F, Hughes WT: Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J. Clin. Invest.81(6),1666–1668 (1988).
  Medline CASGoogle Scholar
• 164  Gigliotti F, Haidaris CG, Wright TW, Harmsen AG: Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun.70(3),1069–1074 (2002).
  Medline CASGoogle Scholar
• 165  Roths JB, Sidman CL: Single and combined humoral and cell-mediated immunotherapy of Pneumocystis carinii pneumonia in immunodeficient SCID mice. Infect. Immun.61(5),1641–1649 (1993).
  Medline CASGoogle Scholar
• 166  Wells J, Gigliotti F, Simpson-Haidaris PJ, Haidaris CG: Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to streptococcus pneumoniae surface antigen PSPA. Infect. Immun.72(3),1548–1556 (2004).
  Medline CASGoogle Scholar
• 167  Wells J, Haidaris CG, Wright TW, Gigliotti F: Complement and fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect. Immun.74(1),390–393 (2006).
  Medline CASGoogle Scholar
• 168  Harmsen AG, Chen W, Gigliotti F: Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect. Immun.63(7),2391–2395 (1995).
  Medline CASGoogle Scholar
• 169  Pascale JM, Shaw MM, Durant PJ et al.: Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect. Immun.67(2),805–809 (1999).
  Medline CASGoogle Scholar
• 170  Garvy BA, Wiley JA, Gigliotti F, Harmsen AG: Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect. Immun.65(12),5052–5056 (1997).
  Medline CASGoogle Scholar
• 171  Wells J, Haidaris CG, Wright TW, Gigliotti F: Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect. Immun.74(4),2446–2448 (2006).
  Medline CASGoogle Scholar
• 172  Wiley JA, Harmsen AG: CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J. Immunol.155(7),3525–3529 (1995).
  Medline CASGoogle Scholar
• 173  Lund FE, Schuer K, Hollifield M, Randall TD, Garvy BA: Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J. Immunol.171(3),1423–1430 (2003).
  Medline CASGoogle Scholar
• 174  Lund FE, Hollifield M, Schuer K, Lines JL, Randall TD, Garvy BA: B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J. Immunol.176(10),6147–6154 (2006).
  Medline CASGoogle Scholar
• 175  Zheng M, Ramsay AJ, Robichaux MB et al.: CD4⁺ T cell-independent DNA vaccination against opportunistic infections. J. Clin. Invest.115(12),3536–3544 (2005).
  Medline CASGoogle Scholar
• 176  Ishimine T, Kawakami K, Nakamoto A, Saito A: Analysis of cellular response and g interferon synthesis in bronchoalveolar lavage fluid and lung homogenate of mice infected with Pneumocystis carinii. Microbiol. Immunol.39(1),49–58 (1995).
  Medline CASGoogle Scholar
• 177  Pesanti EL: Interaction of cytokines and alveolar cells with Pneumocystis cariniiin vitro. J. Infect. Dis.163(3),611–616 (1991).
  Medline CASGoogle Scholar
• 178  Garvy BA, Ezekowitz RA, Harmsen AG: Role of γ interferon in the host immune and inflammatory responses to Pneumocystis carinii infection. Infect. Immun.65(2),373–379 (1997).
  Medline CASGoogle Scholar
• 179  Garvy BA, Gigliotti F, Harmsen AG: Neutralization of interferon-γ exacerbates Pneumocystis-driven interstitial pneumonitis after bone marrow transplantation in mice. J. Clin. Invest.99(7),1637–1644 (1997).
  Medline CASGoogle Scholar
• 180  Shear HL, Valladares G, Narachi MA: Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-γ and reduced doses of trimethoprim/sulfamethoxazole. J. Acquir. Immune Defic. Syndr.3(10),943–948 (1990).
  Medline CASGoogle Scholar
• 181  Beck JM, Liggitt HD, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ: Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of γ interferon. Infect. Immun.59(11),3859–3862 (1991).
  Medline CASGoogle Scholar
• 182  Levy JA: The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol.22(6),312–316 (2001).
  Medline CASGoogle Scholar
• 183  Siegal FP, Fitzgerald-Bocarsly P, Holland BK, Shodell M: Interferon-α generation and immune reconstitution during antiretroviral therapy for human immunodeficiency virus infection. AIDS15(13),1603–1612 (2001).
  Medline CASGoogle Scholar
• 184  Levy DE, Marie I, Prakash A: Ringing the interferon alarm: differential regulation of gene expression at the interface between innate and adaptive immunity. Curr. Opin. Immunol.15(1),52–58 (2003).
  Medline CASGoogle Scholar
• 185  Zhang X, Sun S, Hwang I, Tough DF, Sprent J: Potent and selective stimulation of memory-phenotype CD8⁺ T cells in vivo by IL-15. Immunity8(5),591–599 (1998).
  Medline CASGoogle Scholar
• 186  Meissner N, Rutkowski M, Harmsen AL, Han S, Harmsen AG: Type I interferon signaling and B cells maintain hemopoiesis during Pneumocystis infection of the lung. J. Immunol.178(10),6604–6615 (2007).
  Medline CASGoogle Scholar
• 187  Meissner NN, Swain S, Tighe M, Harmsen A, Harmsen A: Role of type I IFNs in pulmonary complications of Pneumocystis murina infection. J. Immunol.174(9),5462–5471 (2005).▪ Demonstrates that type I IFN signaling mediates the immune response to Pneumocystis.
  Medline CASGoogle Scholar
• 188  Tamburrini E, De Luca A, Ventura G et al.: Pneumocystis carinii stimulates in vitro production of tumor necrosis factor-α by human macrophages. Med. Microbiol. Immunol.180(1),15–20 (1991).
  Medline CASGoogle Scholar
• 189  Kolls JK, Lei D, Vazquez C et al.: Exacerbation of murine Pneumocystis carinii infection by adenoviral-mediated gene transfer of a TNF inhibitor. Am. J. Respir. Cell Mol. Biol.16(2),112–118 (1997).
  Medline CASGoogle Scholar
• 190  Chen W, Havell EA, Harmsen AG: Importance of endogenous tumor necrosis factor α and γ interferon in host resistance against Pneumocystis carinii infection. Infect. Immun.60(4),1279–1284 (1992).
  Medline CASGoogle Scholar
• 191  Dinarello CA: Interleukin-1 and its biologically related cytokines. Adv. Immunol.44,153–205 (1989).
  Medline CASGoogle Scholar
• 192  Roy S, Fitz-Gibbon L, Poulin L, Wainberg MA: Infection of human monocytes/macrophages by HIV-1: effect on secretion of IL-1 activity. Immunology64(2),233–239 (1988).
  Medline CASGoogle Scholar
• 193  Chen W, Havell EA, Moldawer LL, Mcintyre KW, Chizzonite RA, Harmsen AG: Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J. Exp. Med.176(3),713–718 (1992).
  Medline CASGoogle Scholar
• 194  Chen W, Havell EA, Gigliotti F, Harmsen AG: Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect. Immun.61(1),97–102 (1993).
  Medline CASGoogle Scholar
• 195  Linke M, Ashbaugh A, Koch J, Tanaka R, Walzer P: Efficient resolution of Pneumocystismurina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression. J. Med. Microbiol.55(Pt 2),143–147 (2006).
  Medline CASGoogle Scholar
• 196  Jones TC: The effect of granulocyte-macrophage colony stimulating factor (RGM-CSF) on macrophage function in microbial disease. Med. Oncol.13(3),141–147 (1996).
  Medline CASGoogle Scholar
• 197  Mandujano JF, D’Souza NB, Nelson S, Summer WR, Beckerman RC, Shellito JE: Granulocyte-macrophage colony stimulating factor and Pneumocystis carinii pneumonia in mice. Am. J. Respir. Crit. Care Med.151(4),1233–1238 (1995).
  Medline CASGoogle Scholar
• 198  Paine R 3rd, Preston AM, Wilcoxen S et al.: Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J. Immunol.164(5),2602–2609 (2000).
  Medline CASGoogle Scholar
• 199  Denis M, Ghadirian E: Dysregulation of interleukin 8, interleukin 10, and interleukin 12 release by alveolar macrophages from HIV type 1-infected subjects. AIDS Res. Hum. Retroviruses10(12),1619–1627 (1994).
  Medline CASGoogle Scholar
• 200  Ruan S, Mckinley L, Zheng M et al.: Interleukin-12 and host defense against murine Pneumocystis pneumonia. Infect. Immun.76(5),2130–2137 (2008).
  Medline CASGoogle Scholar
• 201  Moore KW, De Waal Malefyt R, Coffman RL, O’garra A: Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.19,683–765 (2001).
  Medline CASGoogle Scholar
• 202  Ruan S, Tate C, Lee JJ, Ritter T, Kolls JK, Shellito JE: Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection. Infect. Immun.70(11),6107–6113 (2002).
  Medline CASGoogle Scholar
• 203  Qureshi MH, Harmsen AG, Garvy BA: IL-10 modulates host responses and lung damage induced by Pneumocystis carinii infection. J. Immunol.170(2),1002–1009 (2003).
  Medline CASGoogle Scholar
• 204  Dubin PJ, Kolls JK: Th17 cytokines and mucosal immunity. Immunol. Rev.226,160–171 (2008).
  Medline CASGoogle Scholar
• 205  Zelante T, Bozza S, De Luca A et al.: Th17 cells in the setting of Aspergillus infection and pathology. Med. Mycol.47(Suppl. 1),S162–S169 (2009).
  Medline CASGoogle Scholar
• 206  Zelante T, De Luca A, D’angelo C, Moretti S, Romani L: IL-17/Th17 in antifungal immunity: what’s new? Eur. J. Immunol.39(3),645–648 (2009).
  Medline CASGoogle Scholar
• 207  Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem.278(3),1910–1914 (2003).
  Medline CASGoogle Scholar
• 208  Mckenzie BS, Kastelein RA, Cua DJ: Understanding the IL-23–IL-17 immune pathway. Trends Immunol.27(1),17–23 (2006).
  Medline CASGoogle Scholar
• 209  Rudner XL, Happel KI, Young EA, Shellito JE: Interleukin-23 (IL-23)–IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun.75(6),3055–3061 (2007).
  Medline CASGoogle Scholar
• 210  Wright TW, Johnston CJ, Harmsen AG, Finkelstein JE: Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect. Immun.67(7),3452–3460 (1999).
  Medline CASGoogle Scholar
• 211  Sauty A, Dziejman M, Taha RA et al.: The T cell-specific CXC chemokines IP-10, MIG, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol.162(6),3549–3558 (1999).
  Medline CASGoogle Scholar
• 212  Gasperini S, Marchi M, Calzetti F et al.: Gene expression and production of the monokine induced by IFN-γ (MIG), IFN-inducible T cell α chemoattractant (I-TAC), and IFN-γ-inducible protein-10 (IP-10) chemokines by human neutrophils. J. Immunol.162(8),4928–4937 (1999).
  Medline CASGoogle Scholar
• 213  Wiley R, Palmer K, Gajewska B et al.: Expression of the Th1 chemokine IFN-γ-inducible protein 10 in the airway alters mucosal allergic sensitization in mice. J. Immunol.166(4),2750–2759 (2001).
  Medline CASGoogle Scholar
• 214  Agostini C, Facco M, Siviero M et al.: CXC chemokines IP-10 and MIG expression and direct migration of pulmonary CD8⁺/CXCR3⁺ T cells in the lungs of patients with HIV infection and T-cell alveolitis. Am. J. Respir. Crit. Care Med.162(4 Pt 1),1466–1473 (2000).
  Medline CASGoogle Scholar
• 215  Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM: Cutting edge: IFN-inducible ELR^-CXC chemokines display defensin-like antimicrobial activity. J. Immunol.167(2),623–627 (2001).
  Medline CASGoogle Scholar
• 216  Crawford MA, Zhu Y, Green CS et al.: Antimicrobial effects of interferon-inducible CXC chemokines against Bacillus anthracis spores and bacilli. Infect. Immun.77(4),1664–1678 (2009).
  Medline CASGoogle Scholar
• 217  Mcallister F, Shellito J, Steele C, Kolls JK: Ip-10 effector activity against Pneumocystis carinii. Presented at: American Thoracic Society. San Diego, CA, USA, 20–25 May 2005.
  Google Scholar